METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests whether a new cell therapy called STEAP1 CAR T, given together with the hormone drug enzalutamide, is safe and effective for men with metastatic castration-resistant prostate cancer (mCRPC). The therapy uses a patient's own immune cells, modified in the lab to be…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could a longer break between prostate cancer treatments boost quality of life?
Disease control Recruiting nowThis phase 3 trial for men with advanced, hormone-resistant prostate cancer tests whether giving the drug lutetium-177 PSMA less often (only when the disease shows signs of activity) can improve quality of life without shortening survival. About 1,500 participants will be randoml…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo aims to supercharge prostate cancer radiation
Disease control Recruiting nowThis study tests whether giving abemaciclib before a radioactive drug (177Lu-PSMA-617) can make prostate cancer cells more sensitive to radiation. About 30 men with advanced, treatment-resistant prostate cancer will receive abemaciclib pills for two weeks, then the radioactive th…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New targeted radiation therapy shows promise for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a drug called 177Lu-PSMA-617, which delivers radiation directly to prostate cancer cells to damage their DNA. It is for people with prostate cancer that has spread and is no longer responding to hormone therapy. The goal is to see if this treatment can slow cance…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug aims to outsmart resistant prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new oral drug called (R)-9bMS in about 18-30 men with metastatic castration-resistant prostate cancer, a form of prostate cancer that has stopped responding to hormone therapy. The drug works by blocking a protein called ACK1, which may help shrink …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: TechnoGenesys, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New PET scan could better spot prostate cancer spread
Diagnosis Recruiting nowThis study tests whether a new type of PET scan (18F-DCFPyL PSMA-PET) can show prostate cancer lesions as well as the standard scan (68Ga-PSMA-11 PET/CT) in 30 men with advanced prostate cancer who are receiving a targeted radiation therapy (177Lu-vipivotide tetraxetan). The goal…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 09:00 UTC